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blockers cause the diabetes, unfortunately, we’re unable to tease
that difference out.
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Dr Gregory Moneta (Portland, Ore). One argument
against use of the perioperative beta blockers has been what
appears to be an increased risk of stroke in patients treated with
beta blockers. Perhaps beta blockers are preventing some small
MIs and other relatively minor cardiac events that don’t really
affect the patient’s quality of life at the risk of causing a stroke
that does affect their quality of life? Did you analyze for strokes
and quality of life in your study? Is it possible perioperative beta
blockers both solve and create problems and the overall effect is
a wash?
Dr Philip Goodney. We shared the same concern about
halfway through this project, when we realized that we were
collecting stroke data for some of the operations in our data set,
but not for all of them. Therefore, that outcome was added about
halfway through for all procedures.
The information that we have shows no effect, but we can’t say
that’s true over the entire length of the study.
In terms of your question about quality of life, it would be
optimal if we had SF-36 scores or some objective measure for
quality of life for all these patients; however, that is beyond the
scope of our project right now.
DrPeter Lawrence (Los Angeles, Calif). Your group hasmade
great contributions in the area of modifying risk factors. My
question has to do with the halo effect of using beta blockers. Do
you have evidence of what’s happened as far as use of statins and
antiplatelet agents? Could their use be a confounding factor in the
unexpected results that you got? Are they using more of these
other agents as well as the beta blockers?
Dr Goodney. We have seen increases, as some of my col-
leagues have presented before, in the use of antiplatelet agents and
statins. In our multivariable model, we saw no effect on postoper-
ative MI from those agents. However, we’re limited, fortunately in
some sense, in the number of high-risk patients that aren’t already
on those medications. Our ability to detect a difference from
statins and antiplatelet agents in terms of outcomes, like postoper-
ativeMI or death, is therefore compromised. It’s not a randomized
trial, and we didn’t have a control arm. So while we hope those
agents are helping, they didn’t have a definitive impact on post-MI
rate in this study.
Dr Sherif Sultan (Galway, Ireland). Regarding the group
who are prolonged on cardioselective beta blockade, they have
fared out so badly. From the results of the ARIC study and the
LIFE trial, it has been shown that cardioselective beta blockers
induce full-blown diabetes mellitus in up to 28% of normal
people. In the context of the results from these large-scale
prospective trials, you have shown in one of your Cox propor-
tional hazards models that diabetic patients have worse results.
Do you think cardioselective beta blockade was influential in
this adverse outcome and that the use of beta-blockers could
have caused your major side effect?
Dr Goodney. We wondered that same question as well. And
we did cross tabulations in that subgroup and saw no direct
relationship. Both of those effects existed independently in terms
of diabetes and beta blockers. So as to whether or not the betaDr Douglas Wooster (Toronto, Ontario, Canada). I think
uideline implementation is an important issue. Oftentimes we see
hat the centers that have the lowest compliance have the largest
mprovement with a guideline implementation strategy. And basi-
ally this is because there is a knowledge gap or perhaps a systems
ssue in those centers.
In your study, you’ve shown actually those groups did not get
p to the accepted level or the anticipated level, whereas you did
ee the incremental slight increase in those places that were doing
ery well. Did you have an explanation for that? Is there something
hat you would modify in taking your program forward, as you
ere saying in your conclusions, to try to improve compliance
cross-the-board with those places that were at the lowest end of
he group?
Dr Goodney. We set the 90% mark, knowing that we had
omewhere between a 5% and an 8% intolerance rate amongst
atients unable to tolerate beta blockers, and therefore the 90%
ark was arbitrary. We gave feedback to each surgeon and to each
enter, and their decision to use beta blocks was independent of
ur initiative. We simply reported the data and encouraged their
se; we didn’t mandate it. We saw increases across all surgeons and
ll centers. While not everybody came up to 90% and maybe there
ere, for whatever reason, a higher proportion of intolerant pa-
ients in some surgeon’s practices.
Dr Olaf Schouten (Rotterdam, The Netherlands). I was
truck by the high incidence of myocardial infarction with chronic
eta blockers. Do you have any information about patients who
ere withdrawn from beta blockers in the perioperative period?
ecause we know if patients have chronic beta blockers and you
top the beta blockade, that these patients have a very high risk of
erioperative MIs.
In your multivariate analysis, patients who have a heart rate
elow 70 beats/minute have a 1.8 increased risk for perioperative
I. It’s difficult for me to understand, because if you dose the beta
lockers correctly, you should be below the 70 beats/minute
hreshold. Do you have an explanation for this?
Dr Goodney. In terms of withdrawing beta blockers, we
on’t have that information and certainly, I suspect, as you alluded
o, that too would represent an even higher risk group.
In terms of heart rate, the reason we analyzed each incremen-
al heart rate, average heart rate was about 77 to 78, at least on
resentation. And the reason that we analyzed the variable was to
ee if the heart rate was very well controlled, if that would push beta
lockers out of the multivariable model. As you know, this would
est if heart rate, really the outcome of interest, was a stronger
redictor of postoperative MI than chronic beta blocker use. And
t turned out it didn’t. And so we really were left with the question:
s this some variable we’re not measuring? Is it BNP? Is it some
ther unmeasurable clinical quantity or is it the beta blockers
hemselves? And we still don’t know.
Dr StephenMurray (Spokane, Wash). So the simple question
s, does the emperor have no clothes?
You’ve just proven that you can increase compliance amongst
noncompliant group, and do so up to close to the 90% level – and
ade absolutely no difference in the long term outcome of these
atients. Have you not just proven the ineffectiveness of beta
lockade?
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May 20111328 GagneDr Goodney. If this was a randomized trial, my worry would
be yes. But, of course, we don’t have the control arm in this. And
we wondered how we might study that. This is a real world study,
so it’s a study in which you need not only highly selected patients
and centers of excellence, you would need real world data. So, to
get appropriately large-scale, one would essentially be limited to
administrative or claims data.
After 2005, Medicare Part D would have that informa-
tion available and you could conceivably study those on beta
blockers and those not on beta blockers. The other alternative
would be to implement another regional quality improvement
group that didn’t study beta blockers to see what happened over
time.
Dr Murray. We’ll look forward to it.
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1Dr Jens Eldrup-Jorgensen (Portland, Ore). Our study did
ave a number of limitations which may explain the lack of impact
f perioperative beta blocks on postoperative myocardial infarc-
ion. The dose was somewhat low, which may have decreased the
ffectiveness of the medication. We had a relatively low number of
igh-risk patients undergoing high-risk operations, and those are
he ones who would be expected to benefit most from being
tarted on beta blockers prior to operation.
To address Dr. Moneta’s question regarding the issue of
troke in patients on perioperative beta blockers, in the POISE
tudy, they used a very high dose of beta blocker which probably
ontributed to hypotension and postoperative stroke. Although
ypotension has been seen in previous studies, POISE is the only
tudy which identified this high incidence of stroke.INVITED COMMENTARYPaul J. Gagne, MD, Norwalk, Conn
In the past decade, business interests and government policy
makers undertook to “refine” the delivery of health care by pro-
posing guidelines that would codify aspects of patient care delivery.
The proposed impetus was to improve quality and decrease costs
for treating conditions like congestive heart failure, surgical infec-
tions, and vascular surgery-related myocardial infarction. The as-
sumption implicit to these guidelines was that physicians and the
health care systems they participate in were not interested in or able
to improve health care with data-driven strategies. The club of
reimbursement was used to drive these quality initiatives, implying
that physician concern for the welfare of their patients was not
adequate to achieve good results.
The excellent article by Goodney et al1 highlights two very
important points to remember and publicize as we go forward in
the debate on health care reform.
The first is that intelligent, well-trained physicians are better
able to care for their patients than are committees who believe they
have a “special ability” to understand “evidence-based medicine.”
Physicians learn early in their training to read the literature with a
critical eye and to determine how best to apply new science to their
patients. Mandated guidelines are only as good as the data they are
based on. They are not able to accommodate specific patient needs,
nor are they nimble enough to adapt to new data the way individ-
ual physicians do daily. The guidelines urging beta-blockers for
vascular patients are a great example of how rushing to “standard-eem to change glacially at times, but I believe this reflects a careful
nd ongoing critical analysis by physicians of “new science” rather
han ignorance or indifference to patient welfare. We practice
vidence-based medicine daily. Unfortunately, the evidence is
ften not as straightforward as the media and pundits would
urport.
The second important point in this report is that physicians,
onvinced that a new therapy or approach is in their patients’ best
nterest, will adopt it. The physicians in this research consortium
uickly and effectively instituted beta-blocker use, expecting to
mprove their patients’ care. This occurred without financial incen-
ives.
I commend the authors for their scientific contribution on the
ole of beta-blockers in vascular surgery. I also thank them for
ffirming what I believe about our profession. As a group, physi-
ians, with our speciality societies, will do what is best for our
atients. We do not need “Big Brother” herding us to achieve this.
e are our patients’ best advocates and wemust resist the efforts of
oliticians, lawyers, business interests, and insurance vendors to
onvince society otherwise.
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